A biomedical startup can successfully complete an NIH Phase II project and still remain years away from commercial launch.

The company may need specialist regulatory expertise, manufacturing development, clinical studies or validation work that falls outside the practical limits of a normal Phase II award.

The NIH SBIR/STTR Commercialization Readiness Pilot, or CRP, exists to support that transition.

The current parent programme is PAR-27-098 and uses the SB1 activity code. The next application deadlines are January 5 and April 5, 2027, followed by standard September, January and April cycles through 2029.

What Is the Commercialization Readiness Pilot?

CRP helps NIH-funded small businesses move late-stage technologies towards a commercially viable product.

It can support both later-stage R&D and specialised technical assistance.

Examples include:

• Regulatory strategy;
• Manufacturing assistance;
• Intellectual-property strategy;
• Market research;
• Independent confirmation of studies;
• Preclinical product development;
• Manufacturing optimisation;
• Design and quality systems;
• Certain clinical studies and clinical trials.

One major advantage is that the company may outsource a substantial portion of the project to specialised external organisations such as CROs.

The small business must still maintain meaningful scientific, financial and administrative oversight.

How Much Can You Receive?

The current SBA guideline for CRP is $4,191,495, although individual NIH institutes frequently impose lower limits.

Current institute limits include:

• NCI: up to the SBA guideline;
• NIA: up to the SBA guideline;
• NIAID: $2 million;
• NIDDK: $2 million;
• NINDS: $2 million;
• NHLBI: $500,000.

CRP projects may last up to three years.

Who Is Eligible?

This programme is not for first-time NIH applicants.

Only U.S. small business concerns that have had an active NIH SBIR or STTR Phase II or Phase IIB award within the previous 36 months can apply.

Companies with currently active or newly awarded qualifying Phase II or Phase IIB projects can also apply.

Only one CRP award is permitted per project.

Does CRP Require Matching Funds?

No.

The parent CRP announcement does not require cost sharing.

This represents a major difference from the Phase IIB Strategic Breakthrough Award, which requires a 100% match.

Consequently, a company with strong technology but insufficient external matching capital may find CRP more practical.

A Regulatory Plan Is Required

CRP applications require a dedicated regulatory plan of up to two pages.

Founders should explain the expected regulatory pathway, approval milestones and relevant interaction with regulators.

Where FDA or another regulatory authority has already provided feedback, the application should explain how that advice affected the development plan.

This requirement means founders should avoid treating regulatory strategy as something to consider only after product development.

Clinical Trial Rules Vary by Institute

The parent programme is clinical-trial optional, but several institutes do not accept clinical trials through CRP.

These include NHLBI, NIAID and NIDDK.

Companies proposing a clinical trial should therefore confirm the correct NIH route before submission.

What Makes a Strong CRP Application?

Start with your existing Phase II results.

Explain what has already been proven and identify the final barriers between the technology and commercial adoption.

The project should not look like an open-ended research programme.

It should have clearly defined commercialisation milestones.

For example, the company may need to establish a scalable GMP manufacturing process, complete an FDA-facing validation study or perform specialised technical work necessary to reach an investment or licensing event.

The application should explain what happens after CRP funding ends and why the company is likely to become less dependent on federal support.

Official Application Route

The next standard deadline is January 5, 2027, followed by April 5.

View the official NIH Commercialization Readiness Pilot PAR-27-098

For Phase II companies approaching the commercialisation gap, CRP can fund exactly the kind of expensive, specialised work that often determines whether a technology remains in development or finally reaches patients.